Figure 2. Withaferin A has in vivo efficacy against DRO 81-1 xenografts without toxicity.

Drug efficacy analysis is plotted out for 8 weeks post-initial tumor injection (since all of the control animals (n=5) have died by 7 weeks post-injection and all of the treated animals (n=5) are alive with tumor). Comparatively even in this small group, treated animals demonstrated a significant survival advantage at this time-point over controls (p<0.01). Tumor growth progression is demonstrated in Figure 2A depicted as an average tumor volume for each group by week (average of all 5 animals per group) with standard error bars. Survival times are depicted in Figure 2B using a Kaplan-Meier format. As a group the treated animals demonstrated a uniform delay-in growth of tumors with 80% of animals demonstrating an initial significant regression in tumor volume at 2 weeks into therapy (week 4 post-tumor implantation) which was followed by eventual disease progression, albeit at a 3 to 4-week growth-delay compared to controls and at a lower growth rate trajectory.